LIDAK PHARMACEUTICALS SELECTS CONDEA Chemie GmbH for Manufacture of n-docosanol
German Company to Produce Active
Ingredient Used in LIDAK's Oral-Facial Herpes Drug
SAN DIEGO, Oct. 22 /PRNewswire/ -- In preparation for the potential
launch of its first product, LIDAK Pharmaceuticals (Nasdaq: LDAKA), today
selected CONDEA Chemie GmbH as manufacturer of the active ingredient in
LIDAK's n-docosanol 10% cream, a topical treatment for oral-facial herpes
infections. CONDEA Vista Company, a U.S. affiliate of CONDEA Chemie GmbH, has
accepted a purchase order to supply sufficient quantities of n-docosanol to
meet product launch requirements.
CONDEA is the name under which RWE-DEA AG of Hamburg, Germany, conducts
its global chemical activities. CONDEA has annual sales of DM 4.7 billion,
and a workforce of 5,150. CONDEA has production sites in Germany, Italy,
China and the U.S., and will manufacture the active ingredient at their plant
in Brunsbettel, Germany.
Gerald J. Yakatan, Ph.D., LIDAK's chief executive officer, in
commenting on the selection of CONDEA, said "We believe the FDA will
make a final decision on n- docosanol before year end. The FDA has
already inspected CONDEA's plant and found it in compliance with cGMP
for the production of n-docosanol. We believe CONDEA has unparalleled
capability to manufacture the highest quality n-docosanol and look forward to
a long business relationship." LIDAK Pharmaceuticals, based in San Diego,
develops therapeutic products designed to treat virally caused diseases,
allergies and asthma.
The information contained in this press release, including any forward
looking statements contained herein, should be reviewed in conjunction
with the Company's Annual Report on Form 10-K and other publicly available
information regarding the Company, copies of which are available from the
Company upon request. Such publicly available information sets forth many
risks and uncertainties related to the Company's business and such statements,
including risks and uncertainties related to drug development and clinical
trials. Final review decisions made by the FDA and other regulatory agencies
concerning clinical trial results are unpredictable and outside of the
influence and/or control of the Company.
SOURCE LIDAK Pharmaceuticals
-0- 10/22/98
/CONTACT: Gregory Hanson, CFO of LIDAK Pharmaceuticals, 619-558-0364,
ext. 210; or Bob Stone, 914-591-5534, home, or Ken DiPaola both of The
Dilenschneider Group, 212-922-0900, for LIDAK/
(LDAKA) |
